Evidence map›Paper›PMID 39557828›Full record

ArticleCell discovery2024

Sodium oligomannate disrupts the adherence of Rib

Xinyi Wang, Zuoquan Xie, Jie Yuan, Enjing Jin, Wen Lian, Shuaishuai Chang, Guangqiang Sun, Zhengnan Feng, Hui Xu, Chen Du and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell discovery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. LRRK2NPJ Parkinson's disease · 2026
    Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Xinyi Wang *State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.ORCID http://orcid.org/0009-0002-6349-8013
Zuoquan Xie *State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.ORCID http://orcid.org/0000-0002-1613-3321
Jie YuanShanghai Green Valley Pharmaceutical Co. Ltd, Shanghai, China.
Enjing JinShanghai Green Valley Pharmaceutical Co. Ltd, Shanghai, China.
Wen LianShanghai Green Valley Pharmaceutical Co. Ltd, Shanghai, China.
Shuaishuai ChangShanghai Green Valley Pharmaceutical Co. Ltd, Shanghai, China.
Guangqiang SunShanghai Green Valley Pharmaceutical Co. Ltd, Shanghai, China.
Zhengnan FengShanghai Green Valley Pharmaceutical Co. Ltd, Shanghai, China.
Hui XuState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Chen DuShanghai Green Valley Pharmaceutical Co. Ltd, Shanghai, China.
Xinying YangShanghai Green Valley Pharmaceutical Co. Ltd, Shanghai, China.
Aihua XiaShanghai Green Valley Pharmaceutical Co. Ltd, Shanghai, China.
Ji QiuShanghai Green Valley Pharmaceutical Co. Ltd, Shanghai, China.
Qingli ZhangInstitutional Technology Service Centre, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Feifei LinInstitutional Technology Service Centre, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Jia LiuInstitutional Technology Service Centre, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.ORCID http://orcid.org/0000-0002-8167-9750
Liang LiShanghai Green Valley Pharmaceutical Co. Ltd, Shanghai, China.
Xiaoguang DuShanghai Green Valley Pharmaceutical Co. Ltd, Shanghai, China.
Zhongping XiaoShanghai Green Valley Pharmaceutical Co. Ltd, Shanghai, China.
Zhou YiShanghai Green Valley Pharmaceutical Co. Ltd, Shanghai, China.
Zhiyu LuoShanghai Green Valley Pharmaceutical Co. Ltd, Shanghai, China.
Changrong GeShanghai Green Valley Pharmaceutical Co. Ltd, Shanghai, China.
Rui LiSchool of Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China.
Mingyue ZhengDrug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.ORCID http://orcid.org/0000-0002-3323-3092
Yi JiangLingang Laboratory, Shanghai, China.ORCID http://orcid.org/0000-0002-0723-1413
Tao WangDepartment of Psychiatry and Affective Disorder Center, Ruijin Hospital Affiliated to Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
Jing ZhangShanghai Green Valley Pharmaceutical Co. Ltd, Shanghai, China.
Qihao GuoDepartment of Gerontology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Meiyu GengState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China. mygeng@simm.ac.cn.ORCID http://orcid.org/0000-0002-7362-0847

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81821005
6 · The paper itself

Abstract

Sodium oligomannate (GV-971), an oligosaccharide drug approved in China for treating mild-to-moderate Alzheimer's disease (AD), was previously found to recondition the gut microbiota and limit altered peripheral Th1 immunity in AD transgenic mice. As a follow-up study, we here made advances by pinpointing a Lactobacillus murinus (L.m.) strain that highly expressed a gene encoding a putative adhesin containing Rib repeats (Rib

Identifiers

PMID39557828
PMCPMC11573985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.